| CalliSpheres®载药微球经动脉导管化疗栓塞治疗肝癌患者的有效性及安全性分析 |
| |
| 引用本文： | 曹国洪,王凯,李佳琪,叶圣利,陈卫飞,王文晶,胡文超.CalliSpheres®载药微球经动脉导管化疗栓塞治疗肝癌患者的有效性及安全性分析[J].中国介入影像与治疗学,2018,15(1):42-46. |
| |
| 作者姓名： | 曹国洪 王凯 李佳琪 叶圣利 陈卫飞 王文晶 胡文超 |
| |
| 作者单位： | 树兰(杭州)医院放射科, 浙江 杭州 310000,树兰(杭州)医院放射科, 浙江 杭州 310000,树兰(杭州)医院放射科, 浙江 杭州 310000,树兰(杭州)医院放射科, 浙江 杭州 310000,树兰(杭州)医院放射科, 浙江 杭州 310000,树兰(杭州)医院放射科, 浙江 杭州 310000,树兰(杭州)医院放射科, 浙江 杭州 310000 |
| |
| 摘 要： | 目的评估CalliSpheres~?载药微球经动脉导管化疗栓塞(DEB-TACE)治疗肝癌患者的有效性及安全性。方法连续纳入20例肝癌患者,均接受DEB-TACE治疗。疗效评价分为完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD),总有效率(ORR)为CR+PR/总例数×100%。结果 DEB-TACE治疗后患者ORR为80.00%(16/20),CR率为40.00%(8/20),PR率为40.00%(8/20),SD率为15.00%(3/20),PD率为5.00%(1/20);单个肿瘤结节的ORR为81.58%(31/38),CR率为50.00%(19/38),PR率为31.58%(12/38),SD率为15.79%(6/38),PD率为2.63%(1/38)。DEB-TACE治疗后,患者的半年无复发生存率为85.00%,半年总体生存率为95.00%。患者仅出现疼痛、发热、恶心、呕吐等轻微不良反应。结论 CalliSpheres~?DEB-TACE治疗肝癌可以达到较好的临床缓解率并有较好的安全性。
|
| 关 键 词： | 化学栓塞 治疗性 肝肿瘤 有效性 安全性 |
| 收稿时间： | 2017/6/14 0:00:00 |
| 修稿时间： | 2017/9/15 0:00:00 |
Efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in treatment of liver cancer patients |
| |
| CAO Guohong,WANG Kai,LI Jiaqi,YE Shengli,CHEN Weifei,WANG Wenjing and HU Wenchao.Efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in treatment of liver cancer patients[J].Chinese Journal of Interventional Imaging and Therapy,2018,15(1):42-46. |
| |
| Authors: | CAO Guohong WANG Kai LI Jiaqi YE Shengli CHEN Weifei WANG Wenjing and HU Wenchao |
| |
| Institution: | Department of Radiology, Shulan[Hangzhou]Hospital, Hangzhou 310000, China,Department of Radiology, Shulan[Hangzhou]Hospital, Hangzhou 310000, China,Department of Radiology, Shulan[Hangzhou]Hospital, Hangzhou 310000, China,Department of Radiology, Shulan[Hangzhou]Hospital, Hangzhou 310000, China,Department of Radiology, Shulan[Hangzhou]Hospital, Hangzhou 310000, China,Department of Radiology, Shulan[Hangzhou]Hospital, Hangzhou 310000, China and Department of Radiology, Shulan[Hangzhou]Hospital, Hangzhou 310000, China |
| |
| Abstract: | Objective To evaluate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treatment of patients with liver cancer. Methods Totally 20 patients with liver cancer undergoing DEB-TACE treatment were enrolled. Clinical efficacy included complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). The overall response rate (ORR) was defined as proportion of patients achieved CR and PR. Results After treatment of DEB-TACE, the ORR, CR, PR, SD, and PD of patients were 80.00% (16/20), 40.00% (8/20), 40.00% (8/20), 15.00% (3/20), and 5.00% (1/20), respectively; while for single tumor nodule, the ORR, CR, PR, SD, and PD were 81.58% (31/32), 50.00 (19/38)%, 31.58% (12/38), 15.79% (6/38), and 2.63% (1/38), respectively. After the treatment of DEB-TACE, the relapse free survival rate in half year was 85.00%, and the overall survival rate was 95.00%. The adverse events of patients were mild pain, fever, nausea and vomiting. Conclusion CalliSpheres® DEB-TACE is an effective and well tolerated treatment in liver cancer patients. |
| |
| Keywords: | Chemoembolization therapeutic Liver neoplasms Efficacy Safety |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国介入影像与治疗学》浏览原始摘要信息 |
| 点击此处可从《中国介入影像与治疗学》下载免费的PDF全文 |
|
